MedCity News J.P. Morgan’s life sciences outlook for 2021 Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021. Shares0 Source: J.P. Morgan To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation. Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector—despite unprecedented business challenges. Here are a few of the highlights: